Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Hari Kotta"'
Publikováno v:
Interdisciplinary Neurosurgery, Vol 27, Iss , Pp 101383- (2022)
Background: Mechanical thrombectomy (MT) is a widely proven method to treat acute ischemic stroke (AIS) during mechanical thrombectomy and acute stenting and angioplasty is a topic discussed till this day regarding safety and efficacy. However, intra
Externí odkaz:
https://doaj.org/article/4f9bd587d5ed41148eefba17d6d6d445
Autor:
Hari Movva, Rani Rabah, Wondwossen Tekle, Alexandros Georgiadis, Laurie Preston, Hari Kotta, Ameer E. Hassan
Publikováno v:
Interdisciplinary Neurosurgery, Vol 23, Iss , Pp 100927- (2021)
Background: Glycoprotein IIb/IIIa inhibitor use in acute ischemic stroke (AIS) during mechanical thrombectomy (MT) and acute stenting and angioplasty is a topic consistently debated due to concerns over safety and efficacy. Tirofiban is a glycoprotei
Externí odkaz:
https://doaj.org/article/fe983e532ef8497faba329a1cd55a892
Publikováno v:
Frontiers in Neurology, Vol 10 (2019)
Background: Previous research has focused on the association between hemorrhagic transformation (HT) incidence and pre-procedural variables (i.e., baseline variables) rather than the association between HT incidence and endovascular treatment (EVT) p
Externí odkaz:
https://doaj.org/article/3225abd7208c46d48ac7559b5fde0f77
Publikováno v:
Interdisciplinary Neurosurgery, Vol 27, Iss, Pp 101383-(2022)
Background Mechanical thrombectomy (MT) is a widely proven method to treat acute ischemic stroke (AIS) during mechanical thrombectomy and acute stenting and angioplasty is a topic discussed till this day regarding safety and efficacy. However, intrav
Autor:
Adnan I Qureshi, Hari Kotta, Umar Shariff, Laurie Preston, Wondwossen G Tekle, Ameer E Hassan
Publikováno v:
Frontiers in Neurology
Frontiers in Neurology, Vol 10 (2019)
Frontiers in Neurology, Vol 10 (2019)
Background: Previous research has focused on the association between hemorrhagic transformation (HT) incidence and pre-procedural variables (i.e., baseline variables) rather than the association between HT incidence and endovascular treatment (EVT) p
Autor:
Hari Kotta, Wondwossen G Tekle, Amrou Sarraj, Ameer E Hassan, Leeroy Garza, Adnan I Qureshi, Laurie Preston
Publikováno v:
Journal of neurointerventional surgery. 11(12)
ObjectiveTo investigate whether significant differences exist in hospital bills and patient outcomes between patients who undergo endovascular thrombectomy (EVT) alone and those who undergo EVT with pretreatment intravenous tissue plasminogen activat
Autor:
Hari Kotta, Wondwossen G Tekle, Laurie Preston, Leeroy Garza, Adnan I Qureshi, Ameer E Hassan, Andrea Pedraza
Publikováno v:
Stroke. 50
Background: Although comprehensive 24/7 endovascular capability and neurocritical care have been effective in the treatment of Subarachnoid Hemorrhage (SAH), studies have shown that there exists a historically significant disparity in providing acces
Autor:
Amrou Sarraj, Wondwossen G Tekle, Laurie Preston, Leeroy Garza, Hari Kotta, Adnan I Qureshi, Ameer E Hassan
Publikováno v:
Stroke. 50
Background: The efficacy of intravenous thrombolytics (IV TPA) administration in conjunction with endovascular treatment (EVT) has recently come into question. If IV TPA does not offer significant patient outcome benefits nor significantly reduce rat
Autor:
Hari Kotta, Adnan I Qureshi, Wondwossen G Tekle, Umar Shariff, Ameer E Hassan, Laurie Preston
Publikováno v:
Stroke. 50
Background: Previous research has primarily investigated the association between hemorrhagic transformation (HT) incidence and baseline variables (i.e. pre-procedural variables) rather than the association between HT incidence and endovascular treatm
Autor:
Ameer E Hassan, Laurie Preston, Wondwossen G Tekle, Hari Movva, Alexandros L. Georgiadis, Hari Kotta, Rani Rabah
Publikováno v:
Interdisciplinary Neurosurgery, Vol 23, Iss, Pp 100927-(2021)
Background Glycoprotein IIb/IIIa inhibitor use in acute ischemic stroke (AIS) during mechanical thrombectomy (MT) and acute stenting and angioplasty is a topic consistently debated due to concerns over safety and efficacy. Tirofiban is a glycoprotein